同為股份(002835.SZ)擬授予117人532.77萬股獎勵股
格隆匯8月24日丨同為股份(002835.SZ)公佈,公司激勵計劃確定首次授予人數共計117人。激勵對象為公司部分高級管理人員及其他管理者、業務骨幹,不包括公司獨立董事、監事及單獨或合計持有公司5%以上股份的股東或實際控制人及其配偶、父母、子女。
本次擬授予的限制性股票所涉及的股票來源為公司向激勵對象發行的人民幣普通股(A股)股票。授予總量由540萬股調整為532.77萬股,其中首次授予數量由432萬股調整為426.22萬股,佔本次限制性股票總量的80%;預留部分由108萬股調整為106.55萬股,佔本次限制性股票總量的20%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.